Table 3.
Disability assessed with the EDSS and MSFC from baseline to week 12
| Patient ID | Baseline | Week 12 | Week 24 | ||||||||||||
| EDSS | T25FW | 9HPT dominant | 9HPT nondominant | Average 9HPT | PASAT3 | MSFC | EDSS | T25FW | 9HPT dominant | 9HPT nondominant | Average 9HPT | PASAT3 | MSFC | EDSS | |
| MS01 | 5.0 | 8.670 | 21.850 | 20.930 | 21.390 | 40 | −0.422 | 4.0 | 9.650 | 19.500 | 20.600 | 20.050 | 57 | −0.160 | 5.5 |
| MS02 | 6.0 | 31.065 | NA | 25.365 | 25.365 | 5 | 0.943 | 6.0 | 41.450 | 120.540 | 22.700 | 71.620 | 60 | 1.662 | 6.0 |
| MS03 | 6.0 | 12.035 | 50.560 | NA | 50.560 | 14 | 0.263 | 6.0 | 11.845 | 42.710 | NA | 42.710 | 30 | −0.399 | 6.0 |
| MS04 | 5.5 | 7.400 | 25.030 | 24.855 | 24.943 | 48 | −0.148 | 5.5 | 7.425 | 31.125 | 30.040 | 30.583 | 57 | −0.003 | 5.5 |
| MS05 | 6.5 | 11.940 | 27.230 | 21.760 | 24.495 | 39 | −0.205 | 6.5 | 13.000 | 30.815 | 23.620 | 27.218 | 46 | −0.243 | 6.5 |
| MS06 | 6.0 | 16.865 | 25.265 | 26.170 | 25.718 | 18 | −0.453 | 6.0 | 10.500 | 25.300 | 26.500 | 25.900 | 28 | −0.816 | 6.0 |
| MS07 | 6.5 | 32.100 | 22.400 | 22.750 | 22.575 | 37 | 0.398 | 6.5 | 43.350 | 20.415 | 23.370 | 21.893 | 48 | 0.395 | 6.5 |
| MS08 | 6.0 | 13.270 | 24.090 | 22.785 | 23.438 | 56 | 0.184 | 6.0 | 9.540 | 19.985 | 20.610 | 20.298 | 55 | −0.213 | 6.0 |
| NMO01 | 3.5 | 4.540 | 18.790 | 19.825 | 19.308 | 58 | −0.247 | 3.5 | 4.795 | 18.705 | 20.535 | 19.620 | 59 | −0.225 | 3.5 |
| NMO02 | 6.0 | 8.725 | 22.565 | 23.180 | 22.873 | 39 | −0.384 | 6.0 | NA | NA | NA | NA | NA | NA | 6.0 |
| NMO03 | 4.5 | 7.050 | 35.205 | 34.685 | 34.945 | 58 | 0.459 | 4.5 | NA | NA | NA | NA | NA | NA | 4.5 |
| NMO04 | 5.0 | 4.835 | 22.925 | 22.935 | 22.930 | 45 | −0.387 | 5.0 | NA | NA | NA | NA | NA | NA | 5.0 |
9HPT, nine hole-peg test; NA, not available; PASAT3, paced auditory serial addition test 3 seconds; T25FW, timed 25 feet walking.